Brief: Pharvaris NV Announces FDA Lifting Of Clinical Hold Of Deucrictibant For The Prophylactic Treatment Of Hae Attacks

Pharvaris NV

22/01/2024 12:21

Jan 22 (Reuters) - Pharvaris NV  PHVS.O :
    * PHARVARIS ANNOUNCES FDA LIFTING OF THE CLINICAL HOLD OF
DEUCRICTIBANT FOR THE PROPHYLACTIC TREATMENT OF HAE ATTACKS
    * PHARVARIS NV: LIFTED CLINICAL HOLD ON INVESTIGATIONAL NEW
DRUG
(IND) APPLICATION FOR DEUCRICTIBANT FOR PROPHYLACTIC TREATMENT
OF HAE
    * PHARVARIS NV: LIFT OF CLINICAL HOLD IN U.S. ENABLES US TO
PROGRESS GLOBAL DEVELOPMENT OF DEUCRICTIBANT FOR LONG-TERM
PROPHYLAXIS
    * PHARVARIS NV: WE WILL REQUEST AN END-OF-PHASE 2 MEETING
WITH FDA
TO ALIGN ON KEY ELEMENTS OF CHAPTER-3

Source text for Eikon:  ID:nGNX813k9 
Further company coverage:  PHVS.O 

 ((Reuters.Briefs@thomsonreuters.com;))